NATIONAL LIPID ASSOCIATION 2019 ANNUAL SCIENTIFIC SESSIONS OBJECTIVES & ACCREDITATION

TARGET AUDIENCE This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management.

TYPE OF ACTIVITY Live Activity; Application

Educational Objectives At the conclusion of this activity, all participants should be able to:  Discuss strategies to improve the knowledge, skills or performance of the healthcare team;

Opening Session: Utilization of Cardiometabolic Therapies for CV Risk Reduction in the Age of Precision Medicine

 Evaluate the efficacy and safety of non-statin therapies used to manage CV risk.  Recognize the role of emerging non-statin therapies in the use of CV risk management.  Assess the implications of ongoing clinical trials for the management of CV risk.

Session I: So Many Guidelines- What’s a Lipidologist to Do?

 Review the 2018 cholesterol guidelines for the diagnosis, management and treatment of at-risk patients.  Evaluate the clinical implications of the 2018 physical exercise guidelines.  Compare the international guidelines for the management of dyslipidemia.

W. Virgil Brown Lecture

 Evaluate the management of patients with dyslipidemia.

Session II: South Asians and risk for ASCVD: Increasing Awareness in Medical and Non-Medical Community

 Recognize the risk factors and interconnection of early onset diabetes and CAD in South Asians.  Discuss practical strategies for diet and physical activity interventions in South Asians.  Describe the role of social media in disease awareness and patient education.

Session III: 2019 Manuscripts

 Explain the issues related to accurate measurement of lipids and lipoproteins in laboratory testing.  Recognize the potential of genetic testing in clinical practice.  Discuss the clinical recommendations for measuring Lipoprotein(a) (Lp(a)) to manage dyslipidemia and risk.

Saturday Morning Keynote: What do we know About Low LDL?

 Determine potential health risks and benefits associated with low LDL.

Session IV: MythBusters in Clinical Lipidology- Pharmacotherapy Debunked

 Analyze common misconceptions regarding pharmacotherapy in the management of patients with dyslipidemia.

Session V: REDUCE-IT to Practice

 Interpret the evidence and clinical implications of recent outcomes trials of omega-3 fatty acids.

Session VI: Women’s Health Sessions

 Identify the appropriate contraceptive options for patients with dyslipidemia.  Critically appraise emerging research and its applications to daily clinical practice.  Explain the impact that hormone replacement therapy can have on postmenopausal patients.  Discuss the risks associated with Polycystic ovary syndrome (PCOS) and its potential impact on metabolic disease.

Session VII: Clinical Pearls

 Critically appraise emerging research and its applications to daily clinical practice.  Compare therapeutic options for the treatment of diabetes.  Explore evidence for the management of statin intolerance through the use of nutraceuticals.

Special Session: Junior Faculty Research Award Presentations

 Discuss the recent research impacting future management of patients with dyslipidemia.

Session VIII: Heart Healthy Eating and Cultural Differences

 Identify the impact of specific diet patterns for the management of dyslipidemia.

Session IX: Top Three Countdown

 Discuss the implications of lipid treatment outcomes trials for the clinical management of patients with dyslipidemia.  Review the publications of new lipid therapies and the application to the management of patients with dyslipidemia.  Identify gaps in the management of dyslipidemia.  Review the practical application of recent publications to the clinical evaluation and management of patients with dyslipidemia.

CRITERIA FOR SUCCESS

Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. Partial credit may be awarded for ACPE credit. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme. The deadline to claim credit is June 14, 2019.

For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

COMMERCIAL SUPPORT

This activity is supported by educational funding provided by and Kowa Pharmaceuticals America, Inc.

OPENING SESSION SUPPORT

This activity is supported by educational funding provided by Esperion Therapeutics.

CREDIT DESIGNATION

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 16.75 AMA PRA Category 1 Credits™ MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CME/CE credit provided by the National Lipid Association

In support of improving patient care, The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Credit Designation Statement The National Lipid Association designates this live activity for a maximum of 16.75 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Dietitians The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 16.50 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.

Pharmacist Accreditation Statement

Universal Activity Number JA0007192-0000-19-009-L01-P (Application) This Activity has been approved for 16.75 contact hour(s) (1.675 CEUs) of the Accreditation Council for Pharmacy Education

Nursing The maximum number of hours awarded for this CE activity is 16.7 contact hours.

For the advanced practice nurse, this activity has 2.8 contact hours of pharmacotherapy content.

DISCLOSURE INFORMATION

FACULTY, PLANNERS, & MODERATORS

Maciej Bancach, MD, PhD, FNLA Advisory Board: Akcea, Amgen, Esperion, Krka Pharma, Consultant: Akcea, Amgen, Krka Pharma, Polfarmex, Sanofi Speaker: Akcea, Amgen, Krka Pharma, Servier, Sanofi

Ginnie Barringer, MS, LDN, CDE, BCADM Speaker: Akcea Spouse- Speaker: Amarin, Amgen, Sanofi- Regeneron

Harold E. Bays, MD, FNLA Consultant: Aegerion, Alnylam, Amgen, AstraZeneca, Esperion, Gemphire, Ionis (ISIS), Janssen, Johnson & Johnson, Kowa, Merck, Metinas, , Prosciento, Regeneron, Sanofi, Takeda Contracted Research: Acasti, Akcea, Alera, , Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Meyers Squibb, Dr. Reddy, Eisai, Eli Lilly, Esperion, Evidera, Gan & Lee, Gemphire, GlaxoSmithKline, Home Access, iSpecimen, Janssen, Johnson & Johnson, LIB, MedImmune, Merck, Metavant, Nektar, Novartis, Novo Nordisk, Omthera, , Qualigen, Regeneron, Sanofi, Selecta, Takeda, TIMI, Urovant Speaker: Amarin, Amgen, Kowa, Regeneron, Sanofi

Kim K. Birtcher, PharmD, CLS, FNLA Scholarly Contributions: Jones & Bartlett Publishing

Vera A. Bittner, MD, MSPH, FNLA Advisory Board: Sanofi Contracted Research: Amgen, AstraZeneca, Bayer, DalCor, Esperion, Sanofi & Regeneron

Alan S. Brown, MD, FNLA Advisory Board: Akcea, Amgen, Kowa Pharmaceuticals America, Inc., Regeneron, sanofi-aventis Speaker: Akcea, Amgen, Kowa Pharmaceuticals America, Inc., Regeneron, sanofi-aventis

Emily Brown, MGC, CGC Has nothing to disclose.

Liam Brunham, MD, PhD Has nothing to disclose.

Brian Cheung, MD Contracted Research: Boston Heart Diagnostics

Mark J. Cziraky, PharmD, CLS, FNLA Has nothing to disclose.

Nihar R. Desai, MD, MPH Consultant: Amgen, Boehringer Ingelheim, Cytokinetics, Novartis, Relypsa Contracted Research: Amgen, Boehringer Ingelheim, Cytokinetics, Novartis, Relypsa

Dave Dixon, PharmD, CLS, FNLA, AACC Has nothing to disclose.

Anuja Dokras, MD, PhD Consultant: AbbVie, Ferring, Medtronic

Casey Elkins, DNP, NP-C, CLS, FNLA Speaker: Regeneron/ Sanofi

Sergio Fazio, MD, PhD, FNLA Advisory Board: Aegerion, Amarin, Amgen, Kowa, Merck & Co., Inc., Sanofi Consultant: Aegerion, Amarin, Amgen, Kowa, Merck & Co., Inc., Sanofi

Mary N. Felando, MS, RDN, FNLA Advisory Board: Akcea Consultant: Akcea

Edward A. Gill, MD, FNLA Has nothing to disclose.

Robert P. Giugliano, MD, SM Consultant: Akcea, Amarin, Amgen, Bristol-Myers Squibb, CVS Caremark, Daiichi-Sankyo, Janssen, Lexicon, Pfizer Contracted Research: Amgen Speaker: Amgen, Daiichi-Sankyo

Anne C. Goldberg, MD, FACP, FNLA Advisory Board: Akcea, Esperion, Novatris Consultant: 23andMe Contracted Research: Akcea, Amarin, Amgen, Pfizer, Regeneron, Sanofi/ Regeneron Scholarly Contributions: Merck & Co., Inc.

Antonio M. Gotto, MD, DPhil, FNLA Advisory Board: Vatera Capital, Spruceview Board of Directors: Esperion Pharmaceuticals, Ionis Pharmaceuticals Consultant: Kowa, Merck, Pfizer Medical Advisor: Stuart & Stevenson

John R. Guyton, MD, FNLA Consultant: Amarin, UpToDate Contracted Research: Amarin, Regeneron/ Sanofi

Alison Hester, PharmD Has nothing to disclose.

Terry A. Jacobson, MD, FNLA Contracted Research: Amarin, Amgen, Regeneron/ sanofi-aventis Consultant: Amarin, Amgen, AstraZeneca, Esperion, Novartis, Regeneron/ sanofi-aventis

Elizabeth Jackson, MSN, ACNS- BS, CLS, FNLA Advisory Board: sanofi-aventis u.s. and Regeneron Pharmaceuticals Speakers Bureau: sanofi-aventis u.s. and Regeneron Pharmaceuticals

Peter H. Jones, MD, FNLA Consultant: Amgen, Merck & Co., Inc., sanofi-aventis U.S., and Regeneron Pharmaceuticals Speaker: Merck & Co., Inc.

Dinesh Kalra, MD Has nothing to disclose.

Ekta Kapoor, MBBS, FACP Has nothing to disclose.

Wahida Karmally, PhD, DrPH, RDN, CDE, CLS, FNLA Consultant: Sesame Workshop Other: Soy Connection Speaker: Akcea

Amit V. Khera, MD, MSc Consultant: Amarin, Color Genomics, Navitor Pharmaceuticals

Carol Kirkpatrick, PhD, RDN, MPH, CLS, FNLA Has nothing to disclose.

Marlys L. Koschinsky, PhD, FNLA Consultant: Amgen, Eli Lilly Contracted Research: CardioVax, Eli Lilly, Ionis, Pfizer Speaker: Eli Lilly, Pfizer

Donald M. Lloyd-Jones, MD, ScM Has nothing to disclose.

Kevin C. Maki, PhD, CLS, FNLA Consultant: ACH Food Companies, Akcea, AstraZeneca, DSM, Egg Nutrition Center, Ingredion, Inc., National Cattlemen’s Beef Association, Pharmavite, LLC, Regeneron, The Global Organization for EPA and DHA Omeaga-3s

Seth S. Martin, MD, MHS Advisory Board: Amgen, Esperion, Novo Nordisk, Regeneron

James M. McKenney, PharmD Has nothing to disclose. Catherine J. McNeal, MD, PhD, FNLA Has nothing to disclose.

Pamela B. Morris, MD, FNLA Advisory Board: Amgen, Sanofi/ Regeneron Contracted Research: Esperion

Saskia Neher, PhD Consultant: Instrumentation Laboratory Contracted Research:

Carl E. Orringer, MD, FNLA Has nothing to disclose.

Heather E. Rasmussen, PhD, RDN Advisor: BetterBiotics

Alan T. Remaley, MD, PhD Contracted Research: Corvidia, LabCorp, MedImmune

Valentina Rodriguez, MD Has nothing to disclose.

Raul D. Santos, MD, MSc, PhD Consultant: Akcea, Amgen, AstraZeneca, Novo Nordisk, Sanofi/Regeneron Contracted Research: Esperion, Kowa Speaker: Amgen, Biolab, Merck, Sanofi/Regeneron

Joseph J. Saseen, PharmD, CLS, FNLA Has nothing to disclose.

Geeta Sikand, RDN, MA, CLS, FNLA Has nothing to disclose.

Shoeb J. Sitafalwalla, MD Has nothing to disclose.

Daniel E. Soffer, MD, FNLA Advisory Board: Akcea Contracted Research: Akcea, Amgen, AstraZeneca, Esperion, Ionis Pharmaceuticals, Kowa, Novartis, Sanofi, Regeneron, Regenex Speakers Bureau: Sanofi

Beth A. Taylor, PhD, FACSM Consultant: Regeneron Contracted Research: Regeneron Other: Monitoring Board- Amgen

James A. Underberg, MD, MS, FNLA Advisory Board: Amgen, Sanofi, Regeneron, Ambry, Alexion, Akcea, Amarin Consultant: Amgen Contracted Research: Aegerion, Pfizer Speakers Bureau: Amgen, Amarin, Aegerion, Alexion, Akcea, Sanofi, Regeneron

Kris Vijay, MD, FNLA Consultant: Amgen, Boehringer Ingelheim, Aventyn, Life 365, Legacy Heart Care Speaker: Novartis, Amgen, Astra Zeneca, Amarin Boehringer Ingelheim, Lilly, Novo Nordisk Salim S. Virani MD, PhD Has nothing to disclose.

Melissa F. Wellons, MD Has nothing to disclose.

Thomas Rhyne White, MD, FNLA Consultant: Amarin Speaker: Amarin, Ionis, Janssen Shareholder: Amarin, Ionis, Johnson & Johnson

Barbara S. Wiggins, PharmD, CLS, FNLA Has nothing to disclose.

Don P. Wilson, MD, FNLA Advisory Board: Alexion Contracted Research: Merck & Co., Inc., Novo Nordisk

Staff Disclosures

NLA Staff Has nothing to disclose.

NLA CME Committee Reviewers

Christie M. Ballantyne, MD, FNLA Consultant: , Akcea, Amarin Corp., Amgen, AstraZeneca, Boehringer- Ingelheim, Denka Seiken, Esperion Therapeutics, Inc., Intercept, Janssen, Matinas BioPharma Holdings, Inc., Merck & Co., Inc., Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, Sanofi- Synthelabo, Inc. Contracted Research: Abbott Laboratories, Akcea, Amgen, Inc., Esperion Therapeutics, Inc., Novartis Pharmaceuticals, Regeneron, Roche Diagnostics, Sanofi- Synthelabo, Inc.

B Alan Bottenberg, DO, FACOI, FNLA Has nothing to disclose.

Kathleen Hawke Byrne, CRNP, BSN, MSN Advisory Board: Amgen

Dave Dixon, PharmD, CLS, FNLA, AACC Has nothing to disclose.

Casey Elkins, DNP, NP-C, CLS, FNLA Speaker: Regeneron/ Sanofi

Edward Mark Goldenberg, MD, FNLA Speaker- Amarin, Amgen, Regeneron

Eric K. Gupta, PharmD, CLS, FNLA Speakers Bureau: Amarin

Susan Halli Demeter, DNP Has nothing to disclose.

Linda C. Hemphill, MD, FNLA Contracted Research: Ionis/ Akcea, The Medicines Company, Regeneron Consultant: Amgen

Donald G. Lamprecht, PharmD, BCPS, CLS, FNLA Has nothing to disclose.

Joel C. Marrs, PharmD, CLS, FNLA Has nothing to disclose.

Pamela B. Morris, MD, FNLA Advisory Board: Amgen, Sanofi/ Regeneron Contracted Research: Esperion

Bertrand N. Mukete, MD Has nothing to disclose.

Saleem Naina, PharmD Has nothing to disclose.

Roda Plakogiannis, PharmD, BS, BCPS, CLS, FNLA Has nothing to disclose.

Joyce L. Ross, MSN, CRNP, CLS, FNLA Advisory Board: Amarin, Esperion Speakers Bureau: Amarin, Amgen, Regeneron, Sanofi

Michael D. Shapiro, DO, FNLA Advisory Board: Esperion Consultant: Amarin

Khalid Hasan Sheikh, MD, FNLA Speakers Bureau: Amarin, Amgen

Scott W. Shurmur, MD, FNLA Has nothing to disclose.

Sean D. Stewart, PharmD, CLS, FNLA Has nothing to disclose.

Wayne S. Warren, MD, FNLA Speaker: Amarin, Amgen

Thomas Rhyne White, MD, FNLA Consultant: Amarin Speaker: Amarin, Ionis, Janssen Shareholder: Amarin, Ionis, Johnson & Johnson

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCTS This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE DECLARATION It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.

DISCLAIMER This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

PERMISSIONS The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.